Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by W. Willenbacher
Nivolumab Plus Doxorubicin, Vinblastine and Dacarbazine for Newly Diagnosed Advanced-Stage Classical Hodgkin Lymphoma: Checkmate 205 Cohort D 2-Year Follow-Up
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
The Best Is Yet to Come – New Drugs in Haematology
Memo - Magazine of European Medical Oncology
Oncology
Hematology
Related publications
Nivolumab for Relapsed/Refractory Classical Hodgkin Lymphoma After Autologous Transplant: Full Results After Extended Follow-Up of the Phase 2 Checkmate 205 Trial
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Long-Term Follow Up of Patients With Human Immunodeficiency Virus Infection and Advanced Stage Hodgkin's Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine and Dacarbazine
Haematologica
Hematology
A Pilot Trial of Adriamycin, Pembrolizumab, Vinblastine and Dacarbazine (Apvd) for Patients With Untreated Classical Hodgkin Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
P1.01-02 Long-Term Outcomes With First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up From CheckMate 012
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Rituximab Plus ABVD in Newly Diagnosed Nodular Lymphocyte-Predominant Hodgkin Lymphoma
British Journal of Haematology
Hematology
Prognostic Implication of the Absolute Lymphocyte to Absolute Monocyte Count Ratio in Patients With Classical Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine or Equivalent Regimens
Oncologist
Cancer Research
Medicine
Oncology
HIV Status Does Not Influence Outcome in Patients With Classical Hodgkin Lymphoma Treated With Chemotherapy Using Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine in the Highly Active Antiretroviral Therapy Era
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Response-Adapted Treatment With Nivolumab and Brentuximab Vedotin in Young Patients With Relapsed/Refractory Classical Hodgkin Lymphoma: Checkmate 744 Subgroup Analyses
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
20-Year Follow-Up of Hodgkin Lymphoma: Predictors of Survival and Secondary Malignancies
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
